Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

High protein intake helps defer frailty in elderly adults

25 Dec 2019

Frailty in very old adults with high protein intake appears to be delayed—an effect that is partly mediated by energy intake, a study reports.

The study used data from the Newcastle 85+ study and included 668 community-dwelling older adults (59 percent female) with complete dietary assessment and Fried frailty status (FFS; baseline and at 1.5, 3 and 5 years of follow-up).

Researchers estimated dietary intake using two-by-24-hour multiple pass recalls at baseline. FFS was based on the following criteria: shrinking, physical endurance/energy, low physical activity, weakness and slow walking speed.

In multistate models, the likelihood of transitioning from prefrail to frail decreased with every one-unit increase in protein intake (g/kg aBW/d; hazard ratio [HR], 0.44, 95 percent confidence interval [CI], 0.25–0.77) but not for the other transitions.

Frailty also occurred less frequently in individuals with protein intakes of ≥0.8 g/kg aBW/d (HR, 0.60, 95 percent CI, 0.43–0.84) and ≥1 g/kg aBW/d (HR, 0.63, 95 percent CI, 0.44–0.90) from 85–90 years of age. When controlled for energy intake, the association was mitigated, although the direction remained the same (eg, g/kg aBW/d model: HR, 0.71, 95 percent CI, 0.36–1.41).

The present data suggest that “protein modulates frailty transitions not only because it provides energy but also for its functional and structural role,” the researchers said. Prevention strategies in very old adults should therefore include provision of protein and energy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.